The present invention relates to novel pyrido-imidazo rifamycins, characterized by a highly selective antibacterial activity and low absorption by oral route.
C07D 471/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Food supplements namely, dietary supplements for general health and well-being; iron based food supplements namely, dietary supplements for anemia and iron deficiencies; ferritin based food supplements namely, dietary supplements for anemia and iron deficiencies
4.
NEW MODUS OF ADMINISTRATION OF IRON, AND NEW FORMULATIONS ADAPTED FOR THE SAID GOAL
The present invention relates to a new modus and a new regimen of administration of divalent iron for therapy of hyposideremia, at the same time reducing toxic side effects, and new formulations containing divalent iron compounds adapted to release iron for intrabuccal absorption, preferably by sublingual absorption, that achieve these objects.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
5.
Low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses
New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
C07H 23/00 - Composés contenant du bore, du silicium ou un métal, p. ex. chélates ou vitamine B12
6.
NEW LOW MOLECULAR WEIGHT COMPLEXES BETWEEN IRON AND MALTOBIONIC ACID, USE THEREOF FOR INTRAMUSCULAR OR SUBCUTANEOUS ADMINISTRATION IN THE TREATMENT OF ANEMIC STATES, AND NEW PHARMACEUTICAL COMPOSITIONS ADAPTED FOR THESE USES
New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.
C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
7.
MIXTURE OF BIOLOGICAL FACTORS ISOLATED FROM COLOSTRUM
A method for obtaining a mixture of biological factors isolated from colostrum, comprising the steps of: a) microdiafiltration of whole colostrum, previously diluted with water or with a saline aqueous solution comprising pharmaceutically acceptable ions so as to yield a volume V1, the microdiafiltration comprising at least one step of filtering the diluted whole colostrum through a cylindrical ceramic membrane with a porosity comprised between 2 and 6 microns, at a temperature comprised between 2°C and 20°C, and at a transmembrane pressure (tmp) comprised between 0.2 bar and 2 bar, obtaining a retentate fraction and a permeate fraction; b) collecting the resulting permeate until its total volume V2 amounts to at least 40% of the volume V1 of initial diluted whole colostrum; c) optional sterilizing filtration of the permeate; and d) optional removal of the water contained in the permeate. The invention also relates to a mixture of biological factors isolated from colostrum which comprises the following quantities of the following active factors, indicated per mg of dry product: 0.15 - 0.35 mg of IgG; 0.01 - 0.05 mg of IgA; 0.5 - 3.0 ng of IGF-1; 30 - 90 pg of TGF β1. The invention also relates to a nutraceutical formulation that comprises the mixture according of the invention and a supplement for milk for newborns, or for follow-on milk or growth milk, or for drinking milk, comprising the mixture of the invention. Finally, the invention relates to milk for newborns, or follow-on milk or growth milk, both in powder form and reconstituted, or drinking milk, supplemented with the mixture of the invention.
Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0.
Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction be tween an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60~C and 100~C for a period between 1 and 4 hours at a pH between 9.0 and 11.0.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07B 37/00 - Réactions sans formation ni introduction de groupes fonctionnels contenant des hétéro-atomes, impliquant soit la formation d'une liaison carbone-carbone entre deux atomes de carbone qui ne sont pas déjà directement liés, soit la séparation de deux atomes de carbone directement liés
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07H 3/00 - Composés contenant uniquement des atomes d'hydrogène et des radicaux saccharide, ces radicaux ne comportant que des atomes de carbone, d'hydrogène et d'oxygène
